ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Core Insights - ARS Pharmaceuticals, Inc. announced the presentation of nine studies at the 2025 AAAAI Annual Scientific Meeting, highlighting the efficacy and safety of neffy, an intranasal epinephrine product for managing anaphylaxis [1][2][20] - Neffy has demonstrated lower symptom scores within 10 minutes compared to traditional intramuscular auto-injectors, supporting its use as a needle-free option for anaphylaxis management [1][19] - The product is indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30 kg or greater [12][20] Company Overview - ARS Pharmaceuticals is focused on empowering at-risk patients and caregivers to manage severe allergic reactions effectively [20] - Neffy is the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis, in both adults and children [2][20] - The company aims to advance scientific knowledge regarding epinephrine administration and improve treatment accessibility for patients [2][20] Research Findings - Studies presented will cover pharmacokinetics and pharmacodynamics of neffy under various conditions, including self-administration and allergic challenges [1][2] - Findings from Japanese and Chinese studies confirm the efficacy and safety of neffy, demonstrating its comparable performance to intramuscular injections [1][19] - The research includes insights into the physiological responses of different age groups to epinephrine administration [6][7] Meeting Activities - The AAAAI Annual Scientific Meeting will feature oral presentations and poster sessions detailing the clinical research on neffy [2][11] - ARS Pharma will host various onsite activities, including a product theatre and an exhibit booth to engage with attendees [11][20]